Nautilus Biotechnology (NASDAQ:NAUT) Trading Down 7.5% – Should You Sell?

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) fell 7.5% during trading on Thursday . The stock traded as low as $0.75 and last traded at $0.75. 209,762 shares were traded during trading, an increase of 30% from the average session volume of 160,889 shares. The stock had previously closed at $0.81.

Nautilus Biotechnology Trading Down 7.5%

The stock has a market capitalization of $94.86 million, a PE ratio of -1.39 and a beta of 1.42. The firm’s fifty day moving average is $0.76 and its 200-day moving average is $1.13.

Nautilus Biotechnology (NASDAQ:NAUT) last issued its quarterly earnings results on Tuesday, April 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. As a group, equities analysts predict that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current year.

Hedge Funds Weigh In On Nautilus Biotechnology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in shares of Nautilus Biotechnology in the fourth quarter valued at approximately $28,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Nautilus Biotechnology in the fourth quarter valued at approximately $34,000. Squarepoint Ops LLC acquired a new stake in shares of Nautilus Biotechnology in the fourth quarter valued at approximately $44,000. Presidio Capital Management LLC boosted its holdings in shares of Nautilus Biotechnology by 246.6% in the second quarter. Presidio Capital Management LLC now owns 34,664 shares of the company’s stock valued at $25,000 after acquiring an additional 24,664 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of Nautilus Biotechnology in the first quarter valued at approximately $31,000. 50.71% of the stock is owned by institutional investors and hedge funds.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.